CORRECTING and REPLACING Vaxenta Inc. Announces Filing of International Patent for Novel Cancer Vaccine

Biotechnology company leverages similarities between pregnancy and cancer in development of unique cancer immunotherapy treatment

CORRECTION...by Vaxenta Biotechnologies

SAN DIEGO--()--Please replace the release with the following corrected version due to multiple revisions.

The corrected release reads:

VAXENTA INC. ANNOUNCES FILING OF INTERNATIONAL PATENT FOR NOVEL CANCER VACCINE

Biotechnology company leverages similarities between pregnancy and cancer in development of unique cancer immunotherapy treatment

Vaxenta Biotechnologies announces the filing of a Patent Cooperation Treaty (PCT) application (SN: PCT/US13/55632) to the World Intellectual Property Organization (WIPO) covering the development of a vaccination therapy against cancer. The international patent has been filed on August 19th, 2013 with a priority date of August 20th, 2012 based on the provisional filing. The filing of this patent, entitled “Placental Vaccination Therapy for Cancer” enables Vaxenta to pursue further stages of development while securing key intellectual property priority dates in the immunotherapy space.

Progressive research has led to Vaxenta’s discovery and development of an innovative immunotherapeutic vaccine called XenUvaX. The product’s unique ability to, “specifically target immune evasion mechanisms used by tumorous growths is anticipated to revolutionize the industry as therapies become tailored toward each individual in a unique and distinct way,” said Boris Markosian, Founder and CEO. The treatment is based on structural and molecular homologies between placental and cancer cells. The invention discloses methods of stimulating an immune response to cancer tissue and biological effectors used by tumors to defeat the host, specifically through immunization.

After examining systems used to protect fetal growth, XenUvaX was created based upon commonalities in immune modulation which occur naturally during pregnancy. Vaxenta’s research determined that proteins involved in immune suppression are unique to placental tissue and have also been detected distinctly in certain tumor growths. The treatment aims at training the body to recognize and learn these mechanisms, effectively stopping key components involved in tumor proliferation. These similarities have proven successful at reducing cancer growth in animal models, preventing angiogenesis, and stopping metastasis. Additionally, the treatment works as a prophylactic, which can be administered either before or after a tumor has been detected.

Pre-clinical studies have been conducted on rodents using both colon and melanoma cancer models indicating reproducible results among different cancer indications with the same product. Vaxenta plans to target melanoma as the initial indication for XenUvaX while expanding research to include prostate, ovarian, breast, bladder and lung cancer. Through successful manufacturing, research, and FDA filings, Vaxenta hopes to expand treatment based on a distinct system which mimics cancer growth yet occurs naturally: pregnancy. According to Boris Markosian, “by teaching the body to respond to a pregnancy-like state, Vaxenta has demonstrated effective tumor regression which will be translated into human application in the near future with IND filings with the FDA. We believe that our work represents a significant milestone in the immunotherapy field, which is showing to be the most effective way to combat cancer when compared to certain toxic chemical treatments.”

The PCT application will allow the company priority rights to intellectual property in over 140 countries as well as help facilitate international expansion. Vaxenta’s goal is to develop its unique immunotherapeutic vaccine to safely recognize, fight and prevent cancer with a treatment that will be readily accessible worldwide in the near future. Vaxenta plans to continue to innovate in the space of immunotherapy and provide a biologic alternative to current chemotherapy and radiotherapy approaches.

www.vaxenta.com

www.twitter.com/Vaxenta

www.facebook.com/pages/Vaxenta-Biotechnologies/214599478711139

Contacts

Vaxenta Biotechnologies
Boris Markosian, CEO, 818-823–3632
Fax: 858-227–9774
Email: bmarkosi@vaxenta.com

XenUvaX administration into mice bearing melanoma resulted in reduction of tumor growth, as compared to animals which received saline control. (Graphic: Business Wire)

XenUvaX administration into mice bearing melanoma resulted in reduction of tumor growth, as compared to animals which received saline control. (Graphic: Business Wire)

???news_view.multimedia.download???

???pagination.previous??? ???pagination.next???

Release Summary

Vaxenta announces International Patent Filing and positive preclinical efficacy data in melanoma and colon cancer

Sharing

Contacts

Vaxenta Biotechnologies
Boris Markosian, CEO, 818-823–3632
Fax: 858-227–9774
Email: bmarkosi@vaxenta.com